Merck, Inc.
🇵🇭Philippines
A Study to Evaluate the Effect of MK-8669 (Ridaforolimus) on QTc Interval in Participants With Advanced Cancer (MK-8669-037)
Phase 1
Completed
- Conditions
- Metastatic or Locally Advanced Cancer
- Interventions
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 23
- Registration Number
- NCT00874731
A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: MK-0941
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 44
- Registration Number
- NCT00873821
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Phase 2
Terminated
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-Cell
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2015-08-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8
- Registration Number
- NCT00871546
The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)
Phase 3
Terminated
- Conditions
- Coronary Artery BypassCardiopulmonary BypassStrokeMyocardial InfarctionVentricular Dysfunction, Left
- Interventions
- Drug: AcadesineDrug: Normal Saline
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3080
- Registration Number
- NCT00872001
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Phase 1
Completed
- Conditions
- Multiple MyelomaLymphoma, Non-HodgkinSolid Tumors
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT00871910
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
Phase 1
Completed
- Conditions
- Multiple MyelomaSolid TumorsLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic. B-Cell
- Interventions
- Drug: SCH 727965
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 123
- Registration Number
- NCT00871663
Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)
Phase 1
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 64
- Registration Number
- NCT00871871
Study of Biomarkers of Airway Inflammation (0000-128)
- First Posted Date
- 2009-03-26
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00869596
A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)
Phase 2
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 118
- Registration Number
- NCT00868790
A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822)
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8
- Registration Number
- NCT00863525
© Copyright 2025. All Rights Reserved by MedPath